This study includes 87 treatment resistance schizophrenia patients. This study will investigate 1)abnormalities of the glutamate level of PFC in patients with schizophrenia compared to healthy controls by using 1H-MRS technique. 2)potential modulation effects of deep transcranial magnetic stimulation(dTMS) on prefrontal cortex function of patients with schizophrenia. 3)the therapeutic efficacy of dTMS on cognitive impairments and other psychotic symptoms of patients with schizophrenia by adopting cognitive function and psychotic symptoms evaluation,as well as to explore the optimal dTMS treatment pattern on cognitive function.
Age
18–50
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients with schizophrenia who meet the dsm-5 diagnostic criteria
Aged from 18 to 55
Right-handedness, normal hearing, visual acuity or corrected visual acuity
Written informed consent of the patient and his/her family
All patients received MINI 7.0 structured interviews
You may not be if
Patients who are currently taking clozapine or who have failed to respond to a full course of treatment with clozapine
Current or past neurological illness,severe physical illness,substance abuse or addiction,alcohol dependence,mental retardation,pregnancy or lactation,extreme agitation, stupor, negative suicide,or those who can not cooperate
